Zalutumumab in Non-curable Patients With SCCHN
Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.
Head and Neck Cancer|Squamous Cell Cancer
DRUG: Zalutumumab
Overall Survival (OS), OS was defined as time from start of treatment until date of death of any cause., From randomization until death, assessed up to 21 months
Objective Tumour Response, Objective Tumour response according to Response Evaluation Criteria in Solid Tumours (RECIST v 1.0). Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the longest diameter of target lesions; Overall Response (OR), CR+PR. Stable disease is Responses not fulfilling CR, PR or progressive disease (PD). PD is At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, OR the appearance of one or more new lesions., During treatment and two weeks after end of treatment, assessed up to 21 months.|Duration of Response, DOR is defined among responders, as the time from the initial documentation of response to the date of disease progression or death, whichever occurs earlier., During treatment and two weeks after end of treatment, assessed up to 21 months|Progression Free Survival (PFS), PFS is defined as the time from start of treatment until disease progression or death., During treatment and two weeks after end of treatment, assessed up to 21 months
Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.